Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer.
10.3857/roj.2013.31.1.18
- Author:
Joo Ho LEE
;
Hong Gyun WU
;
Hak Jae KIM
;
Charn Il PARK
;
Se Hoon LEE
;
Dong Wan KIM
;
Dae Seog HEO
- Publication Type:Original Article
- Keywords:
Non-small-cell lung cancer;
Hypofractionated radiotherapy;
Medically inoperable;
Early stage
- MeSH:
Cisplatin;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Lung;
Lung Neoplasms;
Multivariate Analysis;
Paclitaxel;
Radiotherapy, Conformal;
Retrospective Studies
- From:Radiation Oncology Journal
2013;31(1):18-24
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to assess the clinical outcomes of hypofractionated radiotherapy (HFRT) with three-dimensional conformal technique for medically inoperable patients with early stage non-small-cell lung cancer (NSCLC) and to evaluate prognostic factors. MATERIALS AND METHODS: We performed a retrospective review of 26 patients who underwent HFRT for early stage NSCLC between September 2005 and August 2011. Only clinical stage T1-3N0 was included. The median RT dose was 70 Gy (range, 60 to 72 Gy) and the median biologically equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of patients, 4 Gy per fraction was used. Neoadjuvant chemotherapy with paclitaxel and cisplatin was given to 2 of 26 patients. RESULTS: The median follow-up time for surviving patients was 21 months (range, 13 to 49 months). The overall response rate was 53.9%, and the initial local control rate was 100%. The median survival duration was 27.8 months. Rates of 2-year overall survival, progression-free survival (PFS), local control (LC), and locoregional-free survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. Multivariate analysis showed that BED (>90 vs. < or =90 Gy) was an independent prognostic factor influencing PFS, LC, and LRFS. Severe toxicities over grade 3 were not observed. CONCLUSION: Radical HFRT can yield satisfactory disease control with acceptable rates of toxicities in medically inoperable patients with early stage NSCLC. HFRT is a viable alternative for clinics and patients ineligible for stereotactic ablative radiotherapy. BED over 90 Gy and 4 Gy per fraction might be appropriate for HFRT.
